Indivior Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.3B+12.0% YoYTTM through 30 Jun 2026
Net Income $356M+4,985.7% YoYTTM through 30 Jun 2026
Free Cash Flow -$111MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 80.0% |
| EBITDA Margin | 32.3% |
| Operating Margin | 20.9% |
| Net Margin | 26.8% |
Returns
-214.3%ROE
17.5%ROA
Balance Sheet Health
Debt / Equity-3.26x
Current Ratio0.71x
Net Debt$283M
Cash & Equivalents$222M
Quality Metrics
Altman Z-Score3.47
Piotroski F-Score6 / 9
FCF Margin-8.3%
Rule of 40-8.3
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $1.2B
Diluted EPS$2.79TTMFY2025: $1.64
Dividend
No dividend
Capital Allocation
Capex Intensity5.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| SUBLOCADE | $856M | +13.0% | View detailsIn 2026, SUBLOCADE net revenue is guided to $950 million to $990 million, representing approximately 13% growth at the midpoint. |
| Sublingual Products | $346M |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.